CompletedNCT01637922
Drug Interactions With Hepatitis C Treatment in People Taking Methadone or Buprenorphine
About this title
Read the official source — NCT01637922Medication studyAges 18–64United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 64 years.
- Listed locations
- Atlanta and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateAugust 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 34
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT01637922
- Official title
Show the full official title
Effect of Multiple Dosing With BI 201335 on the Safety, Pharmacokinetics and Pharmacodynamics of Steady-state Methadone and Buprenorphine/Naloxone in Subjects on Stable Addiction Management Therapy
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Atlanta · Overland Park · Salt Lake City
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Boehringer Ingelheim.
Did this study involve medication?
Yes. The study involved medication, including BI 201335.
Who was this study for?
Listed age limits: 18 years to 64 years.
